In summary, we observed CRS-associated AE, preconditioning caused neutropenia and associated infections, which were commonly present in CART treatments and therefore supported safety of CART-aIL6/IL1RA in clinical application. The gene discussed is IL1R1; the disease is congenital rubella syndrome.